This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Articles

Once- Versus Twice-Daily Venlafaxine Therapy in Major Depression: A Randomized, Double-Blind Study

Jay D. Amsterdam, Mary B. Hooper, and Jess Amchin

Published: May 15, 1998

Article Abstract

Background: Psychotropic drug dosing regimens are often based on the pharmacokinetic elimination halflife of the compound. This implies that the pharmacokinetic half-life of the drug may be the critical or sole determinant of pharmacodynamic half-life. In the present study, we examined the safety and efficacy of once- versus twice-daily dosing regimens of the immediate-release formulation of venlafaxine, a serotonin and norepinephrine reuptake site blocker with a short elimination half-life.

Method: Forty-eight patients with a diagnosis of DSM-IV major depressive episode were randomly assigned to once-daily (N=25) versus twice-daily (N=23) venlafaxine. Venlafaxine was started at 37.5 mg daily with specified increments up to 225 mg daily. Efficacy was rated using the Hamilton Rating Scale for Depression (HAM-D), the MontgomeryAsberg Depression Rating Scale (MADRS), and the Clinical Global Impressions scale (CGI).

Results: Twenty-one patients in each group completed 6 weeks of treatment. We observed a significant reduction in mean weekly HAM-D and MADRS scores at weeks 1 through 6 for both dosing groups (p<.001). There were no statistically significant differences in mean HAM-D or MADRS scores between dosing groups at any time point. There was, however, a nonsignificant trend for a more rapid reduction in the mean HAM-D score at week 2 (p<.06) and in the mean MADRS score at week 1 (p<.07) and week 2 (p<.09) in the b.i.d. dosing group. Similarly, there was a significant decrease in the CGI score at week 2 (p<.02) in the b.i.d. dosing group. The rate of adverse events was similar between treatment groups; the most common adverse events were transient nausea and headaches.

Conclusion: These results indicate that the immediate-release formulation of venlafaxine may be safe and effective in some patients when used in a once-daily dose regimen. Moreover, the present results suggest that the short elimination half-life of immediate-release venlafaxine should not be the sole determinant for multiple daily dosing and that antidepressant activity may be more profoundly influenced by a drug’s pharmacodynamic half-life than by its pharmacokinetic half-life.

Volume: 59

Quick Links: Depression (MDD)

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Young-Adult Social Outcomes of Attention-Deficit/Hyperactivity Disorder

ADHD that persisted into young-adulthood was associated with poorer outcomes in terms of education, employment, and emotional...

Read More...